ClinicalTrials.gg
CompletedNCT00452790Updated Sep 21, 2026Results posted

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7 valent pneumococcal conjugate vaccine in Pneumococcal Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 12 sites in India. Open to participants aged 42 Days to 72 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
708
Allocation
Randomized
Ages
42 Days to 72 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
12th of 44
708 · median 328
Started
2007
with 5 others
Phase 3
19 of 44
none open now
Registered
3rd of 44
by date
Lead sponsor
4 of 44
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 12th largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 3rd registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 72 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in India.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • Vaccines, Pneumococcal
04

Who can participate

Ages eligible
42 Days to 72 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infants aged 6 weeks (42-72 days) at time of enrolment
  2. Available for the entire study period

Exclusion criteria

Exclusion Criteria

  1. Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines
  2. A previous anaphylactic reaction to any vaccine or vaccine-related component
  3. to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, or measles vaccines
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
708 participants (actual)

Study arms

  • Experimental
    A

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Active comparator
    B

    Biological: 7 valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (mcg)/mL, 1 Month After the Infant Series.

    Percentage of participants achieving a predefined antibody level of greater than or equal to 0.35 mcg/mL along with the corresponding O'Brien-Fleming-adjusted, exact, 2-sided 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19 A) are presented.

    Time frame: 1 month after the infant series (18 weeks of age)

  2. Percentage of Participants Achieving a Predefined Antibody Level for Concomitant Vaccine Pertussis Antigens (Pertussis Toxoid [PT], Filamentous Hemagglutinin [FHA], Pertactin [PRN]), 1 Month After the Infant Series.

    Percentage of participants achieving a predefined antibody level (measured in enzyme-linked immunosorbent assay \[ELISA\] units per mL \[EU/mL\]) along with the corresponding O'Brien-Fleming-adjusted, exact, 2-sided 95% CI for concomitant antigens pertussis (PT, FHA and PRN) are presented.

    Time frame: 1 month after the infant series (18 weeks of age)

Secondary outcomes

  1. Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 mcg/mL, 1 Month After the Toddler Dose.

    Percentage of participants achieving a predefined antibody level of greater than or equal to 0.35 mcg/mL along with the corresponding exact, 2-sided 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19 A) are presented.

    Time frame: 1 month after the toddler dose (13 months of age)

Other outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody, 1 Month After the 3-Dose Infant Series

    Antibody GMC as measured in mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding O'Brien-Fleming-adjusted, 2-sided 95% CIs were calculated.

    Time frame: 1 month after the 3-dose infant series (18 weeks of age)

  2. GMC for Serotype-specific Pneumococcal IgG Antibody, 1 Month After the Toddler Dose

    Antibody GMC as measured in mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were presented.

    Time frame: 1 month after toddler dose (13 months of age)

  3. Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 1 (6 Weeks of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after the dose 1 of the infant series (6 weeks of age)

  4. Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 2 (10 Weeks of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after the dose 2 of the infant series (10 weeks of age)

  5. Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 3 (14 Weeks of Age)

    Local reactions were reported using an electronic diary by the parent/legal guardian. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration and erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after the dose 3 of the infant series (14 weeks of age)

  6. Percentage of Participants With Pre-specified Local Reactions: Toddler Dose (12 Months of Age)

    Local reactions were reported using an electronic diary by the parent/legal guardian. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration and erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after the toddler dose (12 months of age)

  7. Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 1 (6 Weeks of Age)

    Systemic events (any fever \>=38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after the dose 1 of the infant series (6 weeks of age)

  8. Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 2 (10 Weeks of Age)

    Systemic events (any fever \>=38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after the dose 2 of the infant series (10 weeks of age)

  9. Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 3 (14 Weeks of Age)

    Systemic events (any fever \>=38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after the dose 3 of the infant series (14 weeks of age)

  10. Percentage of Participants With Pre-specified Systemic Events: Toddler Dose (12 Months of Age)

    Systemic events (any fever \>=38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after the toddler dose(12 months of age)

07

Results

Posted Nov 15, 2010
Limitations and caveats
Geometric Mean Concentration Outcome Measures were identified as secondary analysis in the study protocol, but are included to maintain consistency with other postings for this program.

Participant flow

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started354355
Vaccinated dose 1353353
Vaccinated dose 2300300
Vaccinated dose 3221218
Completed219214
Not completed135141
Withdrew: Clinical hold - consent withdrawn118123
Withdrew: Parent/legal guardian request86
Withdrew: Failed to return41
Withdrew: Protocol violation13
Withdrew: Lost to follow-up22
Withdrew: Adverse event12
Withdrew: Other reasons12
Withdrew: Investigator request01
Withdrew: Death01
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC7vPnC
Started219214
Completed198200
Not completed2114
Withdrew: Investigator request1010
Withdrew: Adverse event41
Withdrew: Parent/legal guardian request13
Withdrew: Lost to follow-up40
Withdrew: Failed to return10
Withdrew: Other reasons10
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started198200
Completed198198
Not completed02
Withdrew: Failed to return01
Withdrew: Parent/legal guardian request01

Outcome measures

PrimaryPercentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (mcg)/mL, 1 Month After the Infant Series.

Percentage of participants achieving a predefined antibody level of greater than or equal to 0.35 mcg/mL along with the corresponding O'Brien-Fleming-adjusted, exact, 2-sided 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19 A) are presented.

Time frame:
1 month after the infant series (18 weeks of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (mcg)/mL, 1 Month After the Infant Series.
Percentage of participants13vPnC7vPnC
Common serotypes - serotype 4 (n= 203, 192)97.0 (93.6 to 98.9)97.9 (94.7 to 99.4)
Common serotypes - serotype 6B (n= 196,194)84.7 (78.8 to 89.5)87.1 (81.5 to 91.5)
Common serotypes - serotype 9V (n= 204,195)92.6 (88.1 to 95.8)94.4 (90.1 to 97.2)
Common serotypes - serotype 14 (n= 185,186)91.4 (86.3 to 95.0)93.5 (89.0 to 96.6)
Common serotypes - serotype 18C (n= 204,188)95.1 (91.1 to 97.6)93.1 (88.4 to 96.3)
Common serotypes - serotype 19F (n= 200,188)95.0 (91.0 to 97.6)94.7 (90.4 to 97.4)
Common serotypes - serotype 23F (n= 202,186)90.1 (85.1 to 93.9)89.2 (83.8 to 93.3)
Additional serotypes - serotype 1 (n= 206,195)96.6 (93.1 to 98.6)0.5 (0.0 to 2.8)
Additional serotypes - serotype 3 (n= 201,187)87.6 (82.1 to 91.8)2.1 (0.6 to 5.4)
Additional serotypes - serotype 5 (n= 201,185)85.1 (79.3 to 89.7)24.3 (18.3 to 31.2)
Additional serotypes - serotype 6A (n= 200,191)90.0 (84.9 to 93.8)36.1 (29.3 to 43.4)
Additional serotypes - serotype 7F (n= 203,192)98.0 (95.0 to 99.5)2.6 (0.8 to 6.0)
Additional serotypes - serotype 19 A (n= 204,190)99.5 (97.3 to 100.0)84.7 (78.8 to 89.6)
Other pre-specifiedGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody, 1 Month After the 3-Dose Infant Series

Antibody GMC as measured in mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding O'Brien-Fleming-adjusted, 2-sided 95% CIs were calculated.

Time frame:
1 month after the 3-dose infant series (18 weeks of age)
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody, 1 Month After the 3-Dose Infant Series
mcg/mL13vPnC7vPnC
Common serotypes - serotype 4 (n= 203,192)2.19 (1.95 to 2.46)2.58 (2.26 to 2.95)
Common serotypes - serotype 6B (n= 196,194)1.45 (1.20 to 1.75)1.56 (1.28 to 1.89)
Common serotypes - serotype 9V (n= 204,195)1.34 (1.19 to 1.50)1.46 (1.28 to 1.65)
Common serotypes - serotype 14 (n= 185,186)2.84 (2.35 to 3.43)2.39 (1.98 to 2.90)
Common serotypes - serotype 18C (n= 204,188)1.61 (1.42 to 1.82)1.70 (1.47 to 1.96)
Common serotypes - serotype 19F (n= 200,188)2.25 (1.97 to 2.56)2.47 (2.11 to 2.89)
Common serotypes - serotype 23F (n= 202,186)1.38 (1.18 to 1.60)1.46 (1.25 to 1.70)
Additional serotypes - serotype 1 (n= 206,195)1.95 (1.72 to 2.22)0.03 (0.03 to 0.04)
Additional serotypes - serotype 3 (n= 201,195)0.80 (0.72 to 0.90)0.05 (0.05 to 0.06)
Additional serotypes - serotype 5 (n= 201,195)0.93 (0.82 to 1.06)0.20 (0.18 to 0.23)
Additional serotypes - serotype 6A (n= 200,195)1.44 (1.25 to 1.66)0.28 (0.25 to 0.31)
Additional serotypes - serotype 7F (n= 203,195)2.27 (2.05 to 2.33)0.06 (0.05 to 0.06)
Additional serotypes - serotype 19A (n= 204,195)2.76 (2.46 to 3.10)0.74 (0.66 to 0.82)
PrimaryPercentage of Participants Achieving a Predefined Antibody Level for Concomitant Vaccine Pertussis Antigens (Pertussis Toxoid [PT], Filamentous Hemagglutinin [FHA], Pertactin [PRN]), 1 Month After the Infant Series.

Percentage of participants achieving a predefined antibody level (measured in enzyme-linked immunosorbent assay \[ELISA\] units per mL \[EU/mL\]) along with the corresponding O'Brien-Fleming-adjusted, exact, 2-sided 95% CI for concomitant antigens pertussis (PT, FHA and PRN) are presented.

Time frame:
1 month after the infant series (18 weeks of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Predefined Antibody Level for Concomitant Vaccine Pertussis Antigens (Pertussis Toxoid [PT], Filamentous Hemagglutinin [FHA], Pertactin [PRN]), 1 Month After the Infant Series.
Percentage of participants13vPnC7vPnC
PT >=0.975 EU/mL100.0 (98.2 to 100.0)100.0 (98.1 to 100.0)
FHA >=3.91 EU/mL100.0 (98.2 to 100.0)100.0 (98.1 to 100.0)
PRN >=6 EU/mL92.7 (88.2 to 95.9)95.9 (92.1 to 98.2)
SecondaryPercentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 mcg/mL, 1 Month After the Toddler Dose.

Percentage of participants achieving a predefined antibody level of greater than or equal to 0.35 mcg/mL along with the corresponding exact, 2-sided 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19 A) are presented.

Time frame:
1 month after the toddler dose (13 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 mcg/mL, 1 Month After the Toddler Dose.
Percentage of participants13vPnC7vPnC
Common serotypes - serotype 4 (n= 193, 196)100.0 (98.1 to 100.0)100.0 (98.1 to 100.0)
Common serotypes - serotype 6B (n= 192,195)100.0 (98.1 to 100.0)99.5 (97.2 to 100.0)
Common serotypes - serotype 9V (n= 193,196)99.5 (97.1 to 100.0)99.5 (97.2 to 100.0)
Common serotypes - serotype 14 (n= 193,196)99.5 (97.1 to 100.0)99.5 (97.2 to 100.0)
Common serotypes - serotype 18C (n= 193,196)99.5 (97.1 to 100.0)99.0 (96.4 to 99.9)
Common serotypes - serotype 19F (n= 193,196)97.9 (94.8 to 99.4)98.0 (94.9 to 99.4)
Common serotypes - serotype 23F (n= 193,196)98.4 (95.5 to 99.7)99.5 (97.2 to 100.0)
Additional serotypes - serotype 1 (n= 193,196)98.4 (95.5 to 99.7)3.1 (1.1 to 6.6)
Additional serotypes - serotype 3 (n= 193,196)90.2 (85.1 to 94.0)12.9 (8.5 to 18.4)
Additional serotypes - serotype 5 (n= 192,196)100.0 (98.1 to 100.0)74.3 (67.4 to 80.5)
Additional serotypes - serotype 6A (n= 193,196)100.0 (98.1 to 100.0)92.8 (88.2 to 96.0)
Additional serotypes - serotype 7F (n= 193,196)99.0 (96.3 to 99.9)9.8 (6.0 to 14.9)
Additional serotypes - serotype 19 A (n= 193,196)100.0 (98.1 to 100.0)98.5 (95.5 to 99.7)
Other pre-specifiedGMC for Serotype-specific Pneumococcal IgG Antibody, 1 Month After the Toddler Dose

Antibody GMC as measured in mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were presented.

Time frame:
1 month after toddler dose (13 months of age)
Reported as:
Geometric mean · mcg/mL
GMC for Serotype-specific Pneumococcal IgG Antibody, 1 Month After the Toddler Dose
mcg/mL13vPnC7vPnC
Common serotypes - serotype 4 (n= 193, 196)5.33 (4.69 to 6.04)5.85 (5.13 to 6.68)
Common serotypes - serotype 6B (n= 192, 195)12.24 (10.60 to 14.13)11.60 (9.95 to 13.53)
Common serotypes - serotype 9V (n= 193,196)3.01 (2.68 to 3.37)3.33 (2.96 to 3.75)
Common serotypes - serotype 14 (n= 193,196)10.59 (9.21 to 12.18)10.95 (9.41 to 12.74)
Common serotypes - serotype 18C (n= 193,196)2.63 (2.33 to 2.97)2.98 (2.65 to 3.34)
Common serotypes - serotype 19F (n= 193,196)8.38 (7.11 to 9.87)5.65 (4.84 to 6.58)
Common serotypes - serotype 23F (n= 193,196)4.27 (3.66 to 4.98)5.31 (4.66 to 6.04)
Additional serotypes - serotype 1 (n= 193,196)5.10 (4.39 to 5.92)0.04 (0.04 to 0.05)
Additional serotypes - serotype 3 (n= 193,196)0.91 (0.81 to 1.03)0.09 (0.08 to 0.11)
Additional serotypes - serotype 5 (n= 192,196)3.58 (3.20 to 4.00)0.64 (0.55 to 0.75)
Additional serotypes - serotype 6A (n= 193,196)8.13 (7.11 to 9.28)1.87 (1.62 to 2.17)
Additional serotypes - serotype 7F (n= 193,196)4.81 (4.27 to 5.42)0.06 (0.05 to 0.08)
Additional serotypes - serotype 19A (n= 193,196)14.12 (12.45 to 16.01)3.56 (3.14 to 4.05)
Other pre-specifiedPercentage of Participants With Pre-specified Local Reactions: Infant Series Dose 1 (6 Weeks of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after the dose 1 of the infant series (6 weeks of age)
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 1 (6 Weeks of Age)
Percentage of participants13vPnC7vPnC
Tenderness: Any (n= 347,347)62.559.7
Tenderness: Significant (n= 341,343)42.240.5
Induration: Any (n= 339,342)21.522.5
Induration: Mild (n= 338,340)19.219.1
Induration: Moderate (n= 331,338)4.85.6
Induration: Severe (n= 329,336)0.00.0
Erythema: Any (n= 333,339)12.613.3
Erythema: Mild (n= 333,338)11.411.8
Erythema: Moderate (n= 330,337)1.51.8
Erythema: Severe (n= 329,336)0.00.0
Any of the above (n= 349,348)66.865.2
Other pre-specifiedPercentage of Participants With Pre-specified Local Reactions: Infant Series Dose 2 (10 Weeks of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after the dose 2 of the infant series (10 weeks of age)
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 2 (10 Weeks of Age)
Percentage of participants13vPnC7vPnC
Tenderness: Any (n= 284,282)44.444.0
Tenderness: Significant (n= 278,279)26.628.0
Induration: Any (n= 281,278)20.618.7
Induration: Mild (n= 281,277)16.716.2
Induration: Moderate (n= 273,272)5.14.0
Induration: Severe (n= 273,271)0.00.0
Erythema: Any (n= 275,280)13.817.9
Erythema: Mild (n= 275,279)13.115.8
Erythema: Moderate (n= 273,273)1.52.9
Erythema: Severe (n= 273,271)0.00.0
Any of the above (n= 285,286)51.653.1
Other pre-specifiedPercentage of Participants With Pre-specified Local Reactions: Infant Series Dose 3 (14 Weeks of Age)

Local reactions were reported using an electronic diary by the parent/legal guardian. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration and erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after the dose 3 of the infant series (14 weeks of age)
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 3 (14 Weeks of Age)
Percentage of participants13vPnC7vPnC
Tenderness: Any (n= 204,200)37.338.0
Tenderness: Significant (n= 199,196)24.123.5
Induration: Any (n= 198,195)17.213.8
Induration: Mild (n= 196,195)15.811.8
Induration: Moderate (n= 193,193)2.63.6
Induration: Severe (n= 191,193)0.00.0
Erythema: Any (n= 192,195)10.49.7
Erythema: Mild (n= 192,195)10.49.2
Erythema: Moderate (n= 191,193)0.00.5
Erythema: Severe (n= 191,193)0.00.0
Any of the above (n= 206,202)43.242.1
Other pre-specifiedPercentage of Participants With Pre-specified Local Reactions: Toddler Dose (12 Months of Age)

Local reactions were reported using an electronic diary by the parent/legal guardian. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration and erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after the toddler dose (12 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Local Reactions: Toddler Dose (12 Months of Age)
Percentage of participants13vPnC7vPnC
Tenderness: Any (n= 174,176)29.930.7
Tenderness: Significant (n= 171,170)15.817.1
Induration: Any (n= 173,176)19.717.6
Induration: Mild (n= 170,175)15.914.9
Induration: Moderate (n= 170,171)5.37.6
Induration: Severe (n= 167,169)0.00.0
Erythema: Any (n= 174,176)14.914.2
Erythema: Mild (n= 172,175)12.210.9
Erythema: Moderate (n= 169,170)3.64.1
Erythema: Severe (n= 167,169)0.00.0
Any of the above (n= 177,178)36.741.0
Other pre-specifiedPercentage of Participants With Pre-specified Systemic Events: Infant Series Dose 1 (6 Weeks of Age)

Systemic events (any fever \>=38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after the dose 1 of the infant series (6 weeks of age)
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 1 (6 Weeks of Age)
Percentage of participants13vPnC7vPnC
Fever >=38 but <=39 degrees C (n= 313,324)19.821.6
Fever >39 but <=40 degrees C (n= 309,322)2.31.2
Fever >40 degrees C (n= 309,322)0.30.9
Decreased appetite (n= 343,347)55.755.9
Irritability (n= 345,347)83.279.8
Increased sleep (n= 338,342)40.836.8
Decreased sleep (n= 336,343)55.756.0
Any systemic event (n= 350,348)94.390.8
Other pre-specifiedPercentage of Participants With Pre-specified Systemic Events: Infant Series Dose 2 (10 Weeks of Age)

Systemic events (any fever \>=38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after the dose 2 of the infant series (10 weeks of age)
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 2 (10 Weeks of Age)
Percentage of participants13vPnC7vPnC
Fever >=38 but <=39 degrees C (n= 263,249)10.315.3
Fever >39 but <=40 degrees C (n= 259,247)0.80.4
Fever >40 degrees C (n= 259,247)0.00.4
Decreased appetite (n= 281,282)48.046.5
Irritability (n= 290,291)70.769.8
Increased sleep (n= 285,275)33.726.9
Decreased sleep (n= 282,286)37.946.9
Any systemic event (n= 294,297)80.680.5
Other pre-specifiedPercentage of Participants With Pre-specified Systemic Events: Infant Series Dose 3 (14 Weeks of Age)

Systemic events (any fever \>=38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after the dose 3 of the infant series (14 weeks of age)
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 3 (14 Weeks of Age)
Percentage of participants13vPnC7vPnC
Fever >=38 but <=39 degrees C (n= 181,172)7.714.0
Fever >39 but <=40 degrees C (n= 179,170)0.00.0
Fever >40 degrees C (n= 179,171)0.00.6
Decreased appetite (n= 202,200)42.141.0
Irritability (n= 208,208)64.467.3
Increased sleep (n= 199,195)20.120.5
Decreased sleep (n= 205,201)42.436.8
Any systemic event (n= 213,209)75.178.5
Other pre-specifiedPercentage of Participants With Pre-specified Systemic Events: Toddler Dose (12 Months of Age)

Systemic events (any fever \>=38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after the toddler dose(12 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Systemic Events: Toddler Dose (12 Months of Age)
Percentage of participants13vPnC7vPnC
Fever >=38 but <=39 degrees C (n= 161,154)5.66.5
Fever >39 but <=40 degrees (n= 160,152)0.60.0
Fever >40 degrees C (n= 160,152)0.00.0
Decreased appetite (n= 174,179)28.724.6
Irritability (n= 174,183)38.535.0
Increased sleep (n= 171,170)12.39.4
Decreased sleep (n= 172,178)22.727.0
Any systemic event (n= 179,186)54.752.7

Adverse events

Collected over Baseline through 1 month after last study vaccination (13 Months). Local reactions and systemic events assessed within 4 days of dose: Infant Series Dose 1=6 weeks of age; Dose 2=10 weeks of age; Dose 3=14 weeks of age; Toddler Dose=12 months of age.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infant Series 13vPnC—8/353 (2.3%)330/353 (93.5%)
Infant Series 7vPnC—6/353 (1.7%)316/353 (89.5%)
After the Infant Series 13vPnC—8/353 (2.3%)5/353 (1.4%)
After the Infant Series 7vPnC—11/353 (3.1%)9/353 (2.5%)
Toddler Dose 13vPnC—4/198 (2%)98/198 (49.5%)
Toddler Dose 7vPnC—1/200 (0.5%)98/200 (49%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventInfant Series 13vPnCInfant Series 7vPnCAfter the Infant Series 13vPnCAfter the Infant Series 7vPnCToddler Dose 13vPnCToddler Dose 7vPnC
BronchiolitisInfections and infestations2/3534/3530/3530/3530/1980/200
GastroenteritisInfections and infestations0/3530/3531/3534/3532/1980/200
BronchopneumoniaInfections and infestations3/3530/3531/3531/3531/1980/200
Lower respiratory tract infectionInfections and infestations0/3530/3532/3531/3530/1980/200
Lower respiratory tract infection viralInfections and infestations0/3530/3532/3531/3530/1980/200
Gastroenteritis viralInfections and infestations0/3530/3532/3530/3530/1980/200
DehydrationMetabolism and nutrition disorders0/3530/3532/3531/3530/1980/200
Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders0/3530/3530/3530/3531/1980/200
Breath holdingPsychiatric disorders0/3530/3530/3530/3530/1981/200
Cardiac failure congestiveCardiac disorders1/3530/3530/3531/3530/1980/200
Most frequent other events
Showing 10 of 136
Most frequent other events
EventInfant Series 13vPnCInfant Series 7vPnCAfter the Infant Series 13vPnCAfter the Infant Series 7vPnCToddler Dose 13vPnCToddler Dose 7vPnC
IrritabilityGeneral disorders287/345277/347——67/17464/183
IrritabilityGeneral disorders205/290203/291————
IrritabilityGeneral disorders134/208140/208————
Tenderness (any)Skin and subcutaneous tissue disorders217/347207/347——52/17454/176
Decreased sleepGeneral disorders187/336192/343——39/17248/178
Decreased appetiteGeneral disorders191/343194/347——50/17444/179
Decreased appetiteGeneral disorders135/281131/282————
Decreased sleepGeneral disorders107/282134/286————
Tenderness (any)Skin and subcutaneous tissue disorders126/284124/282————
Decreased sleepGeneral disorders87/20574/201————

Baseline characteristics

Age, Continuous
Age, Continuous(months)13vPnC7vPnCTotal
Mean1.6 ± 0.31.6 ± 0.21.6 ± 0.3
Age, Continuous
Age, Continuous(weeks)13vPnC7vPnCTotal
Mean7.1 ± 1.17.2 ± 1.17.1 ± 1.1
Sex/Gender, Customized
Sex/Gender, Customized(participants)13vPnC7vPnCTotal
Male184186370
Female169169338
Unknown101
08

Study locations

12 sites
  • Sector-12, Chandigarh 160 012, India
  • Sector-32 B, Chandigarh 160031, India
  • Bangalore, Karnataka 560 034, India
  • Bangalore, Karnataka 560017, India
  • Mumbai, Maharashtra 400 026, India
  • Pune, Maharashtra 411 043, India
  • Pune, Maharashtra 411001, India
  • Pune, Maharashtra 411011, India
  • Rajinder Nagar, New Delhi 110 060, India
  • Ludhiana, Punjab 141008, India
  • Chennai, Tamil Nadu 600034, India
  • Vellore, Tamil Nadu 632 004, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Oct 2009 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2007
First posted
Mar 27, 2007
Start
Jun 2007
Primary completionActual
Oct 2009
CompletionActual
Feb 2010
Results first posted
Nov 15, 2010
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00452790
First posted
Mar 27, 2007
Start date
Jun 2007
Primary completion
Oct 2009
Completion
Feb 2010
Results posted
Nov 15, 2010
Last update
Sep 21, 2026

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion